ClinicalTrials.gg
Not yet recruitingNCT07368595CSAGCDUpdated Jun 3, 2026

Comparison of Conjunctival Goblet Cell Density in Dry Eye Patients Treated With Cyclosporine 0.1% Dissolved in Perfluorobutylpentane (Vevye®) or Generic 0.05% Cyclosporine Emulsion for 8 Weeks

A Phase 4 interventional study of Vevye® and Cyclosporine emulsion in Dry Eye Disease (DED), sponsored by Baylor College of Medicine. Not yet recruiting. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-06-03.

Sponsored by Baylor College of Medicine · Phase 4, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 45 studies testing cyclosporine in Dry Eye Syndromes — 5 open to participants now, 5 under way, none of them phase 3. Cyclosporine · Dry Eye Syndromes.

Planned enrollment
17th of 41
60 · median 51
Started
2026
with 3 others
Phase 4
23 of 45
3 open now
Registered
43rd of 45
by date
Lead sponsor
2 of 45
Baylor College of Medicine

Among the 45 studies testing cyclosporine in Dry Eye Syndromes, this one is the 17th largest by planned enrollment of the 41 interventional ones that give a count, is one of 4 that started in 2026, is one of 23 in phase 4, and was the 43rd registered.

Dry Eye Syndromes

1,370 studies on the registry are indexed under Dry Eye Syndromes; 209 are open to participants now.

Browse Dry Eye Syndromes studies →

Open to participants now

5 of the 45 studies testing cyclosporine in Dry Eye Syndromes are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

About cyclosporine

Cyclosporine: first FDA approval 1983 (SANDIMMUNE), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 117 Dry Eye Syndromes studies recruiting now, 74 (63%) set no upper age limit and 24 (21%) stop at 75 or younger; 7 take children under 18; 29 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 45 studies testing cyclosporine in Dry Eye Syndromes, or all of them as a file.
02

Study summary

This goal of this clinical trial is to compare the effects of two approved cyclosporine eye drops that have different concentrations and vehicles on the number of mucus producing conjunctival goblet cells in patients with dry eye disease to learn which one causes the greatest increase.

The main questions it aims to answer are:

Does one drug cause a greater increase in goblet cells? How many weeks does it take to see the difference?

Participants will:

Use the eye drops every day for 2 months Visit the clinic once every 2 weeks for exams and tests

Read the detailed description

Sixty participants with dry eye will be randomized to receive either cyclosporine 0.1% dissolved in perfluorobutylpentane (Vevye®) or 0.05% cyclosporine emulsion (generic Restasis®) to instill in their eyes twice a day for 60 days. The number of mucus producing goblet cells will be measured in the conjunctiva in both eyes by impression cytology. The percentage change in goblet cell number from baseline (before treatment ) at day 60 is the primary endpoint. Treatment groups will also be compared at days 14 and 30.

03

Conditions studied

  • Dry Eye Disease (DED)

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria:

  • 1. Male or female, 18 years of age or older at enrollment. 2. Have a history of DED, clinician diagnosed or patient reported, within the 6 months prior to the enrollment visit.

    3. Have both of these signs of DED in the same eye at the Enrollment (baseline) visit:

    1. Total cornea fluorescein staining score ≥ 3 based on the modified National Eye Institute (NEI) grading scheme.
    2. Total conjunctival lissamine green staining score ≥ 2 based on the modified NEI grading scheme. 4. Unanesthetized Schirmer test score ≥ 5 and \< 15mm/5 min in at least 1 eye at the enrollment visit.

      5. A SANDE eye discomfort visual analog questionnaire score of ≥ 35 at the enrollment visit.

      6. Good general and ocular health, as determined by the investigator using medical history and ophthalmic examination.

      7. Capable of giving signed , which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in this protocol.

      8. Have given written informed consent prior to any study related procedures. 9. Able and willing to follow study instructions and likely to complete all required study visits as assessed by the investigator.

      Exclusion Criteria:

  • Inclusion Criteria:

To be eligible to participate in this trial, an individual must meet all the following criteria:

  1. Male or female, 18 years of age or older at enrollment.
  2. Have a history of DED, clinician diagnosed or patient reported, within the 6 months prior to the enrollment visit.
  3. Have both of these signs of DED in the same eye at the Enrollment (baseline) visit:

    1. Total cornea fluorescein staining score ≥ 3 based on the modified National Eye Institute (NEI) grading scheme.
    2. Total conjunctival lissamine green staining score ≥ 2 based on the modified NEI grading scheme.
  4. Unanesthetized Schirmer test score ≥ 5 and \< 15mm/5 min in at least 1 eye at the enrollment visit.
  5. A SANDE eye discomfort visual analog questionnaire score of ≥ 35 at the enrollment visit.
  6. Good general and ocular health, as determined by the investigator using medical history and ophthalmic examination.
  7. Capable of giving signed informed consent, which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in this protocol.
  8. Have given written informed consent prior to any study related procedures.
  9. Able and willing to follow study instructions and likely to complete all required study visits as assessed by the investigator.

Exclusion Criteria:

Subjects meeting any of the following criteria at the enrollment visit will be excluded from entry into the study:

Ophthalmic:

  1. History or presence of any ocular disorder or condition (other than DED) in either eye that would, in the opinion of the investigator, interfere with the interpretation of the study results or subject safety, such as: significant conjunctival scarring; pterygium or nodular pinguecula; conjunctivitis, or inflammation not associated with DED; anterior blepharitis (Staphylococcal or Demodex).
  2. Other significant ophthalmic disease requiring topical medication (e.g., glaucoma, ocular hypertension), or other ophthalmic disease which the investigator believes may interfere with study findings or interpretation.
  3. History of ocular surgery within 1 year prior to the Screening visit, including punctal cautery, corneal refractive, or anterior segment surgeries (e.g., cataract surgery or any surgery creating limbal or corneal incisions).
  4. History of corneal transplant in one or both eyes.
  5. Diagnosis of recurrent, ongoing, or active ocular infection including, but not limited to herpes simplex or zoster, bacterial or fungal keratitis.
  6. Use of contact lenses in either eye within 90 days prior to the enrollment visit or planned use during the study.
  7. Punctal or intracanalicular plug present in either eyelid within 90 days prior to the enrollment visit or anticipated plug insertion or occlusion at any time during the study.
  8. Regular use, as assessed by the investigator, of lid hygiene or heat masks within 14 days prior to the Enrollment visit or any planned use during the study.
  9. Use of lid heating therapy (i.e., LipiFlow®, iLUX®, Thermal OneTouch, TearCare®) or Meibomian gland probing/therapeutic expression within 90 days prior to enrollment or anticipated during the study.
  10. Use of Intense Pulsed Light (IPL) therapy on eyelids within 90 days prior to enrollment or anticipated during the study.
  11. Use of artificial tears within 24 hours prior to enrollment or anticipated use during the study.
  12. Use of any topical ocular cyclosporine A formulation (e.g., ocular cyclosporine [Restasis®, Cequa™, Vevye™, generics] within 1 year prior to enrollment. Use of lifitegrast [Xiidra®]), perfluorohexyloctane [Meibo™]), Tryptyr™, or any topical ocular , or any non-steroidal-anti-inflammatory agents within 90 days prior to enrollment or anticipated use during the study.
  13. Use of topical ocular autologous serum/plasma within 90 days prior to the enrollment or anticipated use during the study.
  14. Use of any topical ocular glaucoma medication within 30 days prior to enrollment or anticipated use during the study.
  15. Regular use, as defined by the investigator, of any other topical ocular medication not listed in Exclusion 11, 12, 13 or 14 within 14 days prior to the enrollment visit or anticipated use during the study (e.g., eye whitening products [Visine®, Lumify®], topical ocular antibiotics, topical ocular antihistamines, mast cell stabilizers, presbyopia correcting drops [e.g., Vuity™].
  16. Use of Tyrvaya™ (varenicline solution, nasal spray 0.03 mg) within 90 days prior to the enrollment visit or anticipated use during the study.
  17. Use of oral medications for the treatment of severe DED and/or Meibomian gland disease such as oral pilocarpine, oral cevimeline, oral macrolides, oral tetracyclines or tetracycline derivatives, and oral retinoids within 30 days prior to enrollment or anticipated use during the study.
  18. General/Systemic:

    Initiation, discontinuation, or change in dose of a systemic medication known to cause ocular drying (e.g., antihistamines or antidepressants) less than 30 days prior to enrollment or a change in dosage is anticipated during the study. Note: occasional short-term use of these medications, such as systemic antihistamines will be permitted, provided that use was not within 7 days prior to enrollment. Initiation, discontinuation, or change in dose of a systemic corticosteroid less than 60 days prior to the enrollment visit or a change in dosage is anticipated during the study. Note: Non-ocular topically applied corticosteroids (including topical creams, nasal sprays and inhalers) will be permitted during the study, and the dose is not required to be stable.

  19. Initiation, discontinuation, or change in dose of a systemic immunomodulator (e.g., hydroxychloroquine, methotrexate, cyclosporine) less than 60 days prior to the enrollment visit or a change in dosage is anticipated during the study.
  20. Use of an product or device within 30 days prior to the Screening visit.
  21. At the enrollment visit, at the investigator's discretion, have uncontrolled or severe:

    1. Systemic allergy
    2. Rhinitis or sinusitis
    3. Atopic dermatitis involving the eyelids
  22. History or presence of significant systemic disease (i.e.: cardiovascular, pulmonary, hepatic, renal, hematologic, immunologic). Significant is defined as any disease that, in the assessment of the Investigator, would put the safety of the subject at risk through participation, or would prevent or confound protocol-specified assessments (e.g., severe rheumatoid arthritis, severe systemic lupus erythematosus, uncontrolled immunodeficiency disease, etc.).
  23. Known allergies or sensitivity to the study interventions or study diagnostic agents, including sodium fluorescein, lissamine green, etc.
  24. Pregnant at enrollment, currently breastfeeding or plans to become pregnant or breastfeed during the study.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Investigator)
Enrollment
60 participants (estimated)

Study arms

  • Experimental
    Vevye®

    Cyclosporine dissolved in perfluorobutylpentane (Vevye®)

    Drug: Vevye®

  • Active comparator
    Cyclosporine emulsion

    Cyclosporine emulsion

    Drug: Cyclosporine emulsion

Interventions

06

What researchers measure

Primary outcomes

  1. Primary Outcome

    Percentage change from baseline in goblet cell density at Day 60

    Time frame: 60 days

Secondary outcomes

  1. Secondary Outcome 1

    Change from baseline in goblet cell density at Day 60

    Time frame: 60 days

  2. Secondary Outcome 2

    Proportion of subjects with an increase in areas covered by goblet cells at Day 60

    Time frame: 60 days

  3. Secondary Outcome 3

    Proportion of subjects with increase in mean goblet cell density at Day 60

    Time frame: 60 days

  4. Secondary Outcome 4

    Change from baseline in goblet cell density at Days 14 and 30

    Time frame: Days 14 and 30

07

Study locations

No study locations are listed for this record.

08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Sep 2026; primary completion for Mar 2027, 6 months later.

Of 85 non-industry phase 4 interventional studies under Dry Eye Syndromes, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 28. This study's planned 6 months is below that.

Counting every sponsor, half of 113 studies reached it within 12 months; a quarter within 5 and three quarters within 23.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 20, 2026
First posted
Jan 26, 2026
StartEst.
Sep 1, 2026
Primary completionEst.
Mar 31, 2027
CompletionEst.
Jun 2027
Last update
Jun 3, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 3, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07368595
Collaborators
Harrow Inc
Responsible party
Steven Pflugfelder (Professor of Ophthalmology, Baylor College of Medicine) — Principal investigator
First posted
Jan 26, 2026
Start date
Sep 1, 2026 (estimated)
Primary completion
Mar 31, 2027 (estimated)
Completion
Jun 2027 (estimated)
Last update
Jun 3, 2026

Study contacts

Stephen C Pflugfelder, M.D.
Contact
stevenp@bcm.edu
713-798-4732
Jenna Davis, B.S.
Contact
jenna.wilkins@bcm.edu
Stephen C Pflugfelder, M.D.
principal investigator · Baylor College of Medicine

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Cyclosporine

Start the discussion